Kymera Therapeutics Inc [KYMR] stock prices are up 4.54% to $47.02 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KYMR shares have gain 10.87% over the last week, with a monthly amount drifted -2.02%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on November 18, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $65. On August 26, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $65 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $53 on April 22, 2024. Wolfe Research initiated its recommendation with a Peer Perform. JP Morgan upgraded its rating to Overweight for this stock on January 04, 2024. In a note dated January 03, 2024, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $45 to $30.
The stock price of Kymera Therapeutics Inc [KYMR] has been fluctuating between $18.89 and $53.27 over the past year. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $47.02 at the most recent close of the market. An investor can expect a potential return of 9.53% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
The Kymera Therapeutics Inc [NASDAQ:KYMR] reported sales of 87.56M for trailing twelve months, representing a drop of -20.88%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -2.23%, Pretax Profit Margin comes in at -1.91%, and Net Profit Margin reading is -1.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.25 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.50 points at the first support level, and at 43.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.41, and for the 2nd resistance point, it is at 49.81.
Ratios To Look Out For
It’s worth pointing out that Kymera Therapeutics Inc [NASDAQ:KYMR]’s Current Ratio is 8.55. As well, the Quick Ratio is 8.55, while the Cash Ratio is 1.66. Considering the valuation of this stock, the price to sales ratio is 35.95, the price to book ratio is 3.41.
Transactions by insiders
Recent insider trading involved Esposito Pamela, Director, that happened on Sep 17 ’24 when 13500.0 shares were sold. Director, PAMELA ESPOSITO completed a deal on Sep 17 ’24 to buy 13500.0 shares. Meanwhile, Director Albers Jeffrey W. sold 5000.0 shares on Aug 26 ’24.
